Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation.
Tau S, Chamberlin MD, Yang H, Marotti JD, Roberts AM, Carmichael MM, Cressey L, Dragnev C, Demidenko E, Hampsch RA, Soucy SM, Kolling F, Samkoe KS, Alvarez JV, Kettenbach AN, Miller TW. Tau S, et al. Among authors: demidenko e. bioRxiv [Preprint]. 2024 Sep 27:2024.09.26.615177. doi: 10.1101/2024.09.26.615177. bioRxiv. 2024. PMID: 39386444 Free PMC article. Preprint.
Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer.
Traphagen NA, Schwartz GN, Tau S, Jiang A, Hosford SR, Goen AE, Roberts AM, Romo BA, Johnson AL, Duffy EK, Demidenko E, Heverly P, Mosesson Y, Soucy SM, Kolling F, Miller TW. Traphagen NA, et al. Among authors: demidenko e. bioRxiv [Preprint]. 2023 Mar 17:2023.03.16.532956. doi: 10.1101/2023.03.16.532956. bioRxiv. 2023. Update in: Clin Cancer Res. 2023 Sep 15;29(18):3717-3728. doi: 10.1158/1078-0432.CCR-23-0488. PMID: 36993590 Free PMC article. Updated. Preprint.
Oxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
Tau S, Chamberlin MD, Yang H, Marotti JD, Muskus PC, Roberts AM, Carmichael MM, Cressey L, Dragnev CPC, Demidenko E, Hampsch RA, Soucy SM, Kolling FW, Samkoe KS, Alvarez JV, Kettenbach AN, Miller TW. Tau S, et al. Among authors: demidenko e. Cancer Res. 2025 Jan 9. doi: 10.1158/0008-5472.CAN-24-1204. Online ahead of print. Cancer Res. 2025. PMID: 39777474
Does ROSE matter? Evaluation of final diagnostic, PD-L1 immunohistochemistry, and molecular testing yields of CT-guided lung biopsies performed before and after the onset of the COVID-19 pandemic.
Jennings EB, Percarpio RB, Tafe LJ, Demidenko E, Levy J, Gutmann EJ, Marotti JD. Jennings EB, et al. Among authors: demidenko e. J Am Soc Cytopathol. 2024 Jul-Aug;13(4):263-271. doi: 10.1016/j.jasc.2024.03.004. Epub 2024 Mar 29. J Am Soc Cytopathol. 2024. PMID: 38677893
Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models.
Duval KEA, Tavakkoli AD, Kheirollah A, Soderholm HE, Demidenko E, Lines JL, Croteau W, Zhang SC, Wagner RJ, Aulwes E, Noelle RJ, Hoopes PJ. Duval KEA, et al. Among authors: demidenko e. Int J Mol Sci. 2023 Sep 6;24(18):13742. doi: 10.3390/ijms241813742. Int J Mol Sci. 2023. PMID: 37762046 Free PMC article.
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Traphagen NA, Schwartz GN, Tau S, Roberts AM, Jiang A, Hosford SR, Marotti JD, Goen AE, Romo BA, Johnson AL, Duffy EK, Demidenko E, Heverly P, Mosesson Y, Soucy SM, Kolling F, Miller TW. Traphagen NA, et al. Among authors: demidenko e. Clin Cancer Res. 2023 Sep 15;29(18):3717-3728. doi: 10.1158/1078-0432.CCR-23-0488. Clin Cancer Res. 2023. PMID: 37439680 Free PMC article.
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
Schwartz GN, Kaufman PA, Giridhar KV, Marotti JD, Chamberlin MD, Arrick BA, Makari-Judson G, Goetz MP, Soucy SM, Kolling F, Demidenko E, Miller TW. Schwartz GN, et al. Among authors: demidenko e. Clin Cancer Res. 2023 Aug 1;29(15):2767-2773. doi: 10.1158/1078-0432.CCR-23-0112. Clin Cancer Res. 2023. PMID: 37260292 Free PMC article.
137 results